GlassScriptPhysician profile
Charles Keith Connor
NPI 1538102934
$2,090.87
in general payments reported to CMS, 2019-2025
26 companies · $461 in 2025
The $461 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.70 · 2021: $37.82 · 2022: $942 · 2023: $312 · 2024: $323 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,005 · Education: $91.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,005.14 |
| Education | $91.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $555.75 | 2022 | |
| Novartis Pharmaceuticals Corporation | $276.52 | 2022-2025 | |
| Abbvie INC. | $232.32 | 2022-2025 | Venclexta |
| Janssen Biotech, INC. | $154.54 | 2023-2025 | Rybrevant, Darzalex, Tecvayli |
| Blueprint Medicines Corporation | $134.66 | 2022 | |
| Kite Pharma, INC. | $121.36 | 2024 | Yescarta |
| Pharmacyclics LLC, An Abbvie Company | $103.46 | 2022-2023 | Imbruvica, Epkinly |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $61.53 | 2022-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $58.07 | 2022-2024 | Keytruda, Welireg, Lynparza |
| Integra Lifesciences Corporation | $41.72 | 2023 | Duraseal Exact Spinal Sealant System, Cusa Clarity, Codman Hakim |
| Acrotech Biopharma INC. | $37.87 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.75 | 2022 | |
| Pfizer INC. | $28.02 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $22.88 | 2023 | Empaveli |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $22.57 | 2023 | Xgeva, Nplate |
| Ge Healthcare | $20.96 | 2022 | |
| Iovance Biotherapeutics, INC. | $20.02 | 2024 | Amtagvi |
| Taiho Oncology, INC. | $19.82 | 2025 | |
| Array Biopharma INC | $17.28 | 2025 | Lorbrena, Xalkori, Mektovi |
| Genzyme Corporation | $16.50 | 2024 | |
| Rigel Pharmaceuticals, INC. | $16.16 | 2023 | Rezlidhia, Tavalisse |
| Exelixis INC. | $15.70 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Connor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.